Oppenheimer & Co’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.4M Buy
254,090
+15,473
+6% +$902K 0.19% 111
2025
Q4
$12.9M Sell
238,617
-7,180
-3% -$345K 0.18% 117
2025
Q3
$11.1M Buy
245,797
+2,091
+0.9% +$97.7K 0.14% 163
2025
Q2
$11.3M Buy
243,706
+1,197
+0.5% +$58.8K 0.15% 152
2025
Q1
$14.8M Buy
242,509
+27,289
+13% +$1.59M 0.22% 86
2024
Q4
$12.2M Sell
215,220
-18,991
-8% -$1.06M 0.18% 109
2024
Q3
$12.1M Buy
234,211
+30,872
+15% +$1.45M 0.18% 107
2024
Q2
$8.44M Sell
203,339
-15,510
-7% -$694K 0.13% 164
2024
Q1
$11.9M Buy
218,849
+26,519
+14% +$1.35M 0.2% 112
2023
Q4
$9.87M Sell
192,330
-15,254
-7% -$801K 0.18% 122
2023
Q3
$12M Sell
207,584
-24,621
-11% -$1.51M 0.25% 80
2023
Q2
$14.8M Sell
232,205
-2,759
-1% -$185K 0.3% 70
2023
Q1
$16.3M Buy
234,964
+1,720
+0.7% +$121K 0.35% 59
2022
Q4
$16.8M Sell
233,244
-10,412
-4% -$785K 0.38% 49
2022
Q3
$17.3M Sell
243,656
-20,135
-8% -$1.46M 0.41% 45
2022
Q2
$20.3M Sell
263,791
-14,949
-5% -$1.14M 0.44% 40
2022
Q1
$20.4M Buy
278,740
+9,871
+4% +$663K 0.37% 48
2021
Q4
$16.8M Sell
268,869
-25,204
-9% -$1.48M 0.29% 67
2021
Q3
$17.4M Buy
294,073
+13,057
+5% +$860K 0.33% 58
2021
Q2
$18.8M Sell
281,016
-91,557
-25% -$5.97M 0.34% 56
2021
Q1
$23.5M Sell
372,573
-13,343
-3% -$830K 0.47% 30
2020
Q4
$23.9M Buy
385,916
+13,440
+4% +$826K 0.51% 30
2020
Q3
$22.5M Buy
372,476
+6,720
+2% +$404K 0.56% 28
2020
Q2
$21.5M Sell
365,756
-12,325
-3% -$737K 0.56% 34
2020
Q1
$21.1M Buy
378,081
+14,026
+4% +$857K 0.64% 28
2019
Q4
$23.4M Buy
364,055
+62,958
+21% +$3.61M 0.58% 32
2019
Q3
$15.3M Sell
301,097
-3,192
-1% -$150K 0.42% 51
2019
Q2
$13.8M Buy
304,289
+6,298
+2% +$293K 0.38% 56
2019
Q1
$14.2M Sell
297,991
-8,212
-3% -$409K 0.38% 55
2018
Q4
$15.9M Sell
306,203
-35,746
-10% -$1.92M 0.5% 43
2018
Q3
$21.2M Sell
341,949
-569
-0.2% -$33.8K 0.54% 36
2018
Q2
$19M Sell
342,518
-2,437
-0.7% -$132K 0.51% 40
2018
Q1
$21.8M Buy
344,955
+2,050
+0.6% +$132K 0.56% 30
2017
Q4
$21M Sell
342,905
-2,633
-0.8% -$165K 0.54% 34
2017
Q3
$22M Sell
345,538
-12,971
-4% -$757K 0.59% 27
2017
Q2
$20M Buy
358,509
+8,813
+3% +$480K 0.55% 26
2017
Q1
$19M Sell
349,696
-1,995
-0.6% -$109K 0.54% 31
2016
Q4
$20.6M Sell
351,691
-11,339
-3% -$620K 0.6% 26
2016
Q3
$19.6M Buy
363,030
+104,669
+41% +$6.72M 0.57% 28
2016
Q2
$19M Sell
258,361
-20,642
-7% -$1.46M 0.57% 27
2016
Q1
$17.8M Sell
279,003
-4,621
-2% -$291K 0.54% 33
2015
Q4
$19.5M Buy
283,624
+6,518
+2% +$431K 0.58% 29
2015
Q3
$16.4M Sell
277,106
-19,144
-6% -$1.21M 0.5% 37
2015
Q2
$19.7M Buy
296,250
+5,582
+2% +$368K 0.55% 28
2015
Q1
$18.7M Buy
290,668
+5,646
+2% +$353K 0.51% 37
2014
Q4
$16.8M Sell
285,022
-27,392
-9% -$1.54M 0.48% 39
2014
Q3
$16M Sell
312,414
-37,634
-11% -$1.88M 0.48% 35
2014
Q2
$17M Sell
350,048
-22,022
-6% -$1.09M 0.51% 32
2014
Q1
$19.3M Buy
372,070
+47,478
+15% +$2.53M 0.58% 26
2013
Q4
$17.3M Sell
324,592
-29,855
-8% -$1.52M 0.55% 30
2013
Q3
$16.4M Buy
354,447
+36,437
+11% +$1.6M 0.58% 29
2013
Q2
$14.2M Buy
+318,010
New +$13.8M 0.55% 30

Other funds holding BMY

Oppenheimer & Co's BMY Position: Q1 2026 in Review

Oppenheimer & Co increased its Bristol-Myers Squibb (BMY) stake by 6.5% in Q1 2026, buying an estimated $902K and bringing the position to 254,090 shares worth $15.4M. The position accounts for 0.19% of the portfolio, ranked #111.

Oppenheimer & Co first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $23.9M in Q4 2020. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Oppenheimer & Co held 254,090 shares of Bristol-Myers Squibb worth $15.4M as of Q1 2026.
  • Oppenheimer & Co bought 15,473 Bristol-Myers Squibb shares in Q1 2026, an estimated $902K.
  • Bristol-Myers Squibb made up 0.19% of Oppenheimer & Co's portfolio in Q1 2026, its #111 holding.
  • Oppenheimer & Co first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Oppenheimer & Co's Bristol-Myers Squibb position peaked at $23.9M in Q4 2020.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.